FDA clears Philips' AI assistance software for mitral valve repair.

The US Food and Drug Administration has cleared Philips' DeviceGuide, an AI-based software that provides real-time visual assistance during mitral transcatheter edge-to-edge repair. The tool was developed with Edwards Lifesciences, is intended for use with the Edwards PASCAL Ace device, and Philips has not announced a market release date.

Philips has received US Food and Drug Administration clearance for DeviceGuide, an artificial intelligence software intended to provide physicians with real-time visual assistance during mitral valve repair procedures. The software is built on Philips' EchoNavigator echo-fluoro fusion technology, which combines live echocardiography from the EPIQ CVxi cardiovascular platform with live X-ray from the Azurion image-guided therapy system. DeviceGuide was developed in collaboration with Edwards Lifesciences and is described as a tool to streamline workflows for mitral transcatheter edge-to-edge repair (M-TEER). Key details: - DeviceGuide is reported as AI-based software that merges live ultrasound and X-ray images into a consolidated view during procedures. - The software is currently intended for use with the Edwards PASCAL Ace mitral valve repair device, as reported in the article. - Philips did not disclose a commercial release date and said availability is subject to market release and applicable regulatory requirements. - The article explains mitral regurgitation (MR) as a condition where the mitral valve does not close properly, leading to backward blood flow and symptoms such as shortness of breath and fatigue. - Philips described DeviceGuide as built on EchoNavigator technology and integrating EPIQ CVxi echocardiography with the Azurion X-ray platform. - The article mentions Edwards Lifesciences' transcatheter mitral and tricuspid therapies portfolio reached $550.6m in 2025, a 56.4% year-over-year increase. Summary: The FDA clearance permits Philips to market DeviceGuide as an AI visual-assistance tool for use in M-TEER procedures, with development credited to a collaboration with Edwards Lifesciences. Philips has not provided a market release date and has stated that commercial availability depends on market release and regulatory conditions. Undetermined at this time.